Lymphoma Trial, Recruiting NCT06832306 Sponsor: Lungpacer Medical Inc. Condition: Lymphoma
Back to Lymphoma

Lymphoma Trial, Recruiting

NCT06832306
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older, of any sex
  • People who are able to give their own consent, or who have a legally authorised representative or substitute decision maker who can give consent on their behalf
  • People who developed new breathing problems or a sudden decline in breathing function within the 2 weeks before needing breathing support
  • People whose blood oxygen levels are low, as measured by specific medical tests or breathing support settings (confirm with trial site for exact measurements), or who are already receiving certain treatments for low oxygen levels such as inhaled medicines to open blood vessels in the lungs, or are being treated by being positioned face-down on a ventilator
  • People who have been on a mechanical ventilator in an intensive care unit (ICU) for less than 96 hours (4 days) at the time of joining the trial
  • People whose treating doctor expects them to need continued mechanical ventilation for at least 48 hours after joining the trial

Who may not be able to join:

  • People whose low oxygen levels are mainly caused by a flare-up of chronic obstructive pulmonary disease (a long-term lung condition), severe asthma attack, fluid in the lungs due to heart problems, or a blood clot in the lungs
  • People with a pre-existing long-term lung disease that may make recovery and coming off the ventilator difficult, such as COPD or lung scarring (pulmonary fibrosis)
  • People who have an abnormal connection between an airway and the space around the lung at the time of assessment
  • People who require a form of life support that works outside the body to do the work of the heart and lungs (ECMO)
  • People with a pre-existing condition affecting the nervous system, nerves, or muscles — including known injury to the nerve that controls the main breathing muscle (the diaphragm) — that could affect breathing
  • People with a body mass index (BMI) above 70 kg/m²
  • People for whom placing a catheter (a thin tube) into certain specific veins on the left side of the neck or chest is not medically safe, for example due to infection, known narrowing of those veins, or other complications at those sites
  • People whose care is expected to shift entirely to comfort or palliative care within 72 hours of joining the trial
  • People with severe long-term liver disease, as assessed by a specific medical scoring system (confirm with trial site)
  • People whose treating doctor does not consider enrolment to be medically appropriate for them
  • People who are currently taking part in another clinical trial of an investigational medicine or device that could affect the results of this trial
  • People who have any implanted or external electrical device that could interact with or be affected by the trial device — this includes devices such as nerve stimulators, brain pacemakers, heart pacemakers, or defibrillators
  • People who are known or suspected to be pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Ewan Goligher, MD, PhD, FRCPC, Toronto General Hospital

Phone: (612) 986-7172

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Lungpacer Medical Inc.
Registry
ClinicalTrials.gov
Start date
28 May 2025
Est. completion
1 June 2026

Where this trial is recruiting

🇨🇦 Canada 🇺🇸 United States

Primary endpoints

Successful device insertion, mapping, and initiation of stimulation within 18 hours of meeting readiness-to-stimulate criteria; Stimulation delivered on >50% of ventilator-triggered breaths (ascertained from continuous recordings stored in the Console); Rehabilitation sessions delivered at least once per day on >50% of days when the patient was breathing in assisted (patient-triggered) mechanical ventilation

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov